Why a gene therapy for beta thalassemia is a slow-moving miracle

Shelby Campbell's experience with a gene therapy for beta thalassemia is the story of a brave girl fighting a rare blood disorder.

December 13, 2023 Check out STAT+

Sponsored By

Amanda Berg for STAT Gene therapy offered this 7-year-old freedom. The price: a grueling year Shelby Campbell's experience with a gene therapy for beta thalassemia is the story of a brave girl fighting a rare blood disorder. By Brittany Trang Supreme Court will decide abortion pill access The Supreme Court agreed Wednesday to take on whether Americans can access a commonly used abortion pill, mifepristone. By Sarah Owermohle STAT+ | After decade-long dispute over CRISPR-Cas9, Editas strikes deal with Vertex to cash in The licensing deal follows a bruising, decade-long fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool. By Jason Mast GABRIEL MONNET/AFP via Getty Images STAT+ | Could sickle cell someday be treated not with CRISPR, but with a pill? Even with gene therapies now available, researchers say the world need simpler drugs for sickle cell. Novartis may have found one. By Jason Mast Doctors call out ableism in cancer care: 'The biggest accommodation is attitude' Outdated methods to make decisions on cancer treatment can put patients with a disability at a disadvantage. By Elizabeth Cooney Opinion: Exceptions to abortion restrictions often fail people like Kate Cox whose babies are sure to die Kate Cox's case in Texas makes it clear: Medical exceptions to anti-abortion laws don't help people whose babies are sure to die. By Abigail Wilpers Sandy Huffaker for STAT STAT+ | Vertex non-opioid drug reduces chronic nerve pain in mid-stage study The results support the biotech company's efforts to develop an effective painkiller without the addictive potential of opioids. By Adam Feuerstein and Jonathan Wosen STAT+ | Male birth control gets another shot with small new trial of non-hormonal pill A non-hormonal birth control pill for men, now entering a Phase 1 trial, offers a chance to consider new approaches toward contraception. By Annalisa Merelli

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser